

HOO-IMM PLUS: a multi target Next-gen drug over ARVs

The major obstacle in the eradication of HIV is the presence of small pools of cells harboring an integrated HIV viral DNA (Proviral DNA). With the ARVs therapy or its interruption, these integrated viral DNA harboring cells produces virus, like before, resulting treatment failure.

HOO-IMM PLUS aims at functional cure by intensified integrase inhibition that prevents viral integration within the cell thereby reducing proviral latency, completely eliminates with long term therapy.

HOO-IMM therapy distinct from its competitor like ARVs that could not able to inhibit integrase activity at 3' processing reaction, initial step of viral integration causing viral latency, a next generation target for drug discovery. No such ARVs licensed till date in such Class (3' Processing/ Non Catalytic activity) of integrase inhibition.

The HOO-IMM PLUS medication found to be very clinically potent for reducing plasma viremia also declining the proviral latency with the help of intensified integrase inhibition therapy that has been proven in the invitro anti-HIV testing with 97.89% inhibition. There is a significant observed decline in proviral DNA load within 6 months interval time of treatment of patients received New upgraded PLUS.

| DRUG COMBINATION | Reverse Transcriptase Inhibitor | Integrase Inhibitor | |
|----------------------|---------------------------------|-------------------------|---------------------------|
| | | 3' processing Inhibitor | Strand transfer Inhibitor |
| TEE ARVs Combination | ✓ | ✗ | ✗ |
| TLD ARVs Combination | ✓ | ✗ | ✓ |
| HOO-IMM PLUS | ✓ | ✓ | ✓ |